Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -9.16%54 Intrinsic Value: Projected FCF is $62.69 as of Sep. 03, 2026. GuruFocus rates UPC with a GF Score™ of 54/100 and a GF Value™ of $2.76 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 633 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 99.37% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Universe Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
UPC'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.06 Med: 0.07 Max: 0.08
Current: 0.07
During the past 8 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Universe Pharmaceuticals was 0.08. The lowest was 0.06. And the median was 0.07.
UPC's Price-to-Projected-FCF is ranked better than 99.37% of 633
companies
in the Drug Manufacturers industry
Industry Median: 1.56
vs UPC: 0.07
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Universe Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
4.36
/
62.688853869553
=
0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals Intrinsic Value: Projected FCF Related Terms
Universe Pharmaceuticals Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Universe Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CTTH, PRFX, CVSI: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $62.69 mean?
Universe Pharmaceuticals (UPC) has a Intrinsic Value: Projected FCF of $62.69 as of Sep. 03, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Universe Pharmaceuticals and its competitors. According to the industry distribution chart, Universe Pharmaceuticals ranks #4 out of 633 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Universe Pharmaceuticals' Intrinsic Value: Projected FCF too high?
Universe Pharmaceuticals' current Intrinsic Value: Projected FCF is $62.69. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.56. Universe Pharmaceuticals' value of $62.69 is 3918.6% above this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #4 out of 633 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Intrinsic Value: Projected FCF compare to CTTH and PRFX?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #4 out of 633 companies for Intrinsic Value: Projected FCF. This places Universe Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.56. Universe Pharmaceuticals' value of $62.69 is 3918.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.56, based on 633 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current Intrinsic Value: Projected FCF of $62.69 is 3918.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Intrinsic Value: Projected FCF is $62.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.76, compared to a current price of $4.36 — trading 58% above its estimated fair value. The current Intrinsic Value: Projected FCF is $62.69 and 3918.6% above the Drug Manufacturers industry median of 1.56. Universe Pharmaceuticals' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Intrinsic Value: Projected FCF is $62.69 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $4.36 is trading 58% above its estimated GF Value™ of $2.76.
GuruFocus considers Universe Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for UPC:
Intrinsic Value: Projected FCF: $62.69
GF Value™: $2.76 vs. price of $4.36 (58% above fair value)
Industry Position: 3918.6% above the Drug Manufacturers median (#4 of 633)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
54GF Score
Get the complete analysis for UPC
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
